Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13043154 | 0.87 | POLB (0.53) | ALDH1A1TDP1POLBCYP3A4HTT | |
| SCHEMBL15054397 | 0.86 | KDM4E (0.46) | KDM4EALDH1A1TDP1POLBCYP3A4 | |
| SCHEMBL14220842 | 0.84 | KDM4E (0.49) | KDM4EALDH1A1TDP1POLBCYP3A4 | |
| SCHEMBL38658388 | 0.83 | TSHR (0.53) | ALDH1A1TDP1POLBCYP3A4HTT | |
| SCHEMBL1819544 | 0.83 | TSHR (0.53) | ALDH1A1TDP1POLBCYP3A4HTT | |
| SCHEMBL15835003 | 0.82 | POLB (0.52) | KDM4EALDH1A1TDP1POLBCYP3A4 | |
| SCHEMBL1817741 | 0.82 | HTT (0.41) | ALDH1A1TDP1POLBCYP3A4HTT | |
| SCHEMBL7122749 | 0.81 | TDP1 (0.55) | KDM4EALDH1A1TDP1POLBCYP3A4 | |
| SCHEMBL27865322 | 0.81 | CYP1A2 (0.50) | KDM4EALDH1A1TDP1POLBCYP3A4 | |
| SCHEMBL10340437 | 0.81 | ALDH1A1 (0.58) | KDM4EALDH1A1TDP1POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174974-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | KDM4E 1811/4885ALDH1A1 2542/4885TDP1 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.